These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 23142289

  • 1. Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo.
    Yu W, Gu K, Yu Z, Yuan D, He M, Ma N, Lai S, Zhao J, Ren Z, Zhang X, Shao C, Jiang GL.
    Cancer Lett; 2013 Feb 01; 329(1):109-17. PubMed ID: 23142289
    [Abstract] [Full Text] [Related]

  • 2. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
    Dai XF, Ding J, Zhang RG, Ren JH, Ma CM, Wu G.
    Int J Radiat Biol; 2013 Sep 01; 89(9):724-31. PubMed ID: 23682582
    [Abstract] [Full Text] [Related]

  • 3. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
    Huang CY, Tai WT, Hsieh CY, Hsu WM, Lai YJ, Chen LJ, Shiau CW, Chen KF.
    Cancer Lett; 2014 Jul 28; 349(2):136-43. PubMed ID: 24735751
    [Abstract] [Full Text] [Related]

  • 4. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    Hsu FT, Liu YC, Chiang IT, Liu RS, Wang HE, Lin WJ, Hwang JJ.
    Int J Oncol; 2014 Jul 28; 45(1):177-88. PubMed ID: 24807012
    [Abstract] [Full Text] [Related]

  • 5. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y, Zheng T, Song R, Wang J, Yin D, Wang L, Liu H, Tian L, Fang X, Meng X, Jiang H, Liu J, Liu L.
    Hepatology; 2013 May 28; 57(5):1847-57. PubMed ID: 23299930
    [Abstract] [Full Text] [Related]

  • 6. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
    Zhao D, Zhai B, He C, Tan G, Jiang X, Pan S, Dong X, Wei Z, Ma L, Qiao H, Jiang H, Sun X.
    Cell Signal; 2014 May 28; 26(5):1030-9. PubMed ID: 24486412
    [Abstract] [Full Text] [Related]

  • 7. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C.
    Cancer Res; 2006 Dec 15; 66(24):11851-8. PubMed ID: 17178882
    [Abstract] [Full Text] [Related]

  • 8. Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model.
    Chen JC, Chuang HY, Hsu FT, Chen YC, Chien YC, Hwang JJ.
    Oncotarget; 2016 Dec 20; 7(51):85450-85463. PubMed ID: 27863427
    [Abstract] [Full Text] [Related]

  • 9. Sorafenib modulates the radio sensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent manner.
    Li Q, Hu Y, Xi M, He L, Zhao L, Liu M.
    BMC Cancer; 2012 Oct 22; 12():485. PubMed ID: 23088517
    [Abstract] [Full Text] [Related]

  • 10. Heterogeneous sensitivity of hepatocellular carcinoma to sorafenib revealed by the short-term culture of tumor fragments.
    Godin C, Dupont S, Ezzoukhry Z, Louandre C, Chatelain D, Henaut L, Sabbagh C, Regimbeau JM, Maziere JC, Barbare JC, Chauffert B, Galmiche A.
    Anticancer Res; 2013 Apr 22; 33(4):1415-20. PubMed ID: 23564781
    [Abstract] [Full Text] [Related]

  • 11. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice.
    Lo J, Lau EY, Ching RH, Cheng BY, Ma MK, Ng IO, Lee TK.
    Hepatology; 2015 Aug 22; 62(2):534-45. PubMed ID: 25902734
    [Abstract] [Full Text] [Related]

  • 12. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N, Streit S, Wybranski C, Jürgens J, Brauner J, Schulz N, Powerski M, Ricke J, Kalinski T, Dudeck O, Seidensticker M.
    Anticancer Res; 2017 Jan 22; 37(1):87-93. PubMed ID: 28011478
    [Abstract] [Full Text] [Related]

  • 13. Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation.
    Honma Y, Harada M.
    Exp Cell Res; 2013 Aug 15; 319(14):2166-78. PubMed ID: 23727131
    [Abstract] [Full Text] [Related]

  • 14. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression.
    Hsieh SC, Tsai JP, Yang SF, Tang MJ, Hsieh YH.
    Amino Acids; 2014 Dec 15; 46(12):2809-22. PubMed ID: 25245054
    [Abstract] [Full Text] [Related]

  • 15. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells.
    Sprinzl MF, Reisinger F, Puschnik A, Ringelhan M, Ackermann K, Hartmann D, Schiemann M, Weinmann A, Galle PR, Schuchmann M, Friess H, Otto G, Heikenwalder M, Protzer U.
    Hepatology; 2013 Jun 15; 57(6):2358-68. PubMed ID: 23424039
    [Abstract] [Full Text] [Related]

  • 16. Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-κB expression in vitro and in vivo.
    Kuo YC, Lin WC, Chiang IT, Chang YF, Chen CW, Su SH, Chen CL, Hwang JJ.
    Biomed Pharmacother; 2012 Feb 15; 66(1):12-20. PubMed ID: 22265104
    [Abstract] [Full Text] [Related]

  • 17. Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.
    Morisaki T, Umebayashi M, Kiyota A, Koya N, Tanaka H, Onishi H, Katano M.
    Anticancer Res; 2013 Apr 15; 33(4):1387-95. PubMed ID: 23564777
    [Abstract] [Full Text] [Related]

  • 18. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
    Zhai B, Zhang X, Sun B, Cao L, Zhao L, Li J, Ge N, Chen L, Qian H, Yin Z.
    Tumour Biol; 2016 Jun 15; 37(6):8047-55. PubMed ID: 26711788
    [Abstract] [Full Text] [Related]

  • 19. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells.
    Louandre C, Marcq I, Bouhlal H, Lachaier E, Godin C, Saidak Z, François C, Chatelain D, Debuysscher V, Barbare JC, Chauffert B, Galmiche A.
    Cancer Lett; 2015 Jan 28; 356(2 Pt B):971-7. PubMed ID: 25444922
    [Abstract] [Full Text] [Related]

  • 20. Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
    Peng S, Wang Y, Peng H, Chen D, Shen S, Peng B, Chen M, Lencioni R, Kuang M.
    Hepatology; 2014 Oct 28; 60(4):1264-77. PubMed ID: 24849467
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.